Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-Mutant Advanced NSCLC
NCT02834936Phase 2Completed
- Sponsor
- Hengrui
- Start
- Oct 2016
- Primary completion
- Jun 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Oct 2016; status: completed.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02834936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834936.